Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cystine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1976

Metabolism of cystine by Merino sheep genetically different in wool production IV. Rates of entry of cystine into plasma, measured with a single intravenous injection of L-[35S]cystine, and the subsequent incorporation of 35S into wool fibres.

Ten, 2-year-old Merino ewes from a flock selectively bred for high clean fleece weight (Fleece Plus) and ten from a flock bred for low clean fleece weight (Fleece Minus) were randomly divided between two dietary treatments: 600 or 1100 g/day of pelleted lucerne hay. After 14 weeks, each ewe received an intravenous injection of L-[35S]cystine (66-4 muCi). Venous blood samples were collected at 15 specified times until 8 h after the injections, and wool fibres were plucked until 65-75 days after the injections. Protein-free filtrates prepared from blood plasma were bulked within sample times for ewes from the same flock and dietary treatment. Equations relating the specific radioactivity of free cystine isolated from the bulked filtrates to time after injection contained three exponential terms. The entry rate and pool size of cystine estimated from these equations were greater in Fleece Minus than in Fleece Plus ewes (by 25 and 44% respectively for entry rate and pool size). Both traits were also higher in ewes offered 1100 g lucerne/day than in those offered 600 g/day (58-7 v. 33-9 mg/h for entry rate and 19-2 v 11-8 mg for pool size). The concentration of free cystine in plasma was greater in ewes offered 1100 g lucerne/day (3-0 v 2-1 mg/1; P less than 0-05), and greater in Fleece Minus ewes (3-0 v. 2-1 mg/l; P less than 0-05). The percentage of the injected radioactivity recovered in the wool clipped to day 70 post-injection differed between genotypes and between dietary treatments (P less than 0.05), being greater in Fleece Plus than in Fleece Minus ewes, and greater in those offered 1100 g lucerne/day than in those offered 600 g/day. The relationships between 35S incorporated per 1000 fibres (R) and time after injection (t) were best fitted by equations of the form (formula: see text). For all sheep, n = 3. The coefficient of the second term was significantly greater (P less than 0-05) in ewes offered 1100 g lucerne/day, whilst the constant of this term was significantly greater in Fleece Minus ewes. The specific radioactivities of cystine incorporated into wool fibres (SRf) during various intervals of time after injection were derived from these equations and from the measured rates of output of cystine in wool. The equations computed to relate SRf to time after injection (t) were of the form (formula: see text). Again there were three components. The coefficient of the third component was significantly greater (P less than 0-05) in ewes offered 1100 g lucerne/day, whilst the constant of the second term was significantly greater in Fleece Minus ewes.

Animals↗
PubMed1975

Hormone and enzyme assays in pregnancy. V. A rapid method for measuring the placental cystine-aminopeptidase using 1-cystine-bis-1-cystine-bis-p-nitroanilide-nitroanilide as substrate.

A rapid and simple method for determination of the placental cystine-aminopeptidase (P-CAP) activity in plasma is presented. The enzyme-catalysed hydrolysis of the substrate, 1-cystine-bis-p-nitroanilide, is followed in a spectrophotometer by reading the absorbance of the product p-nitroaniline at 380 nm. The absorbance increases linearily with time after a lag-period of 30 seconds to 5 min. The reaction is followed for about 10 min and the increase in absorbtion per min is calculated from the linear part of the absorbtion curve. The test could also be performed by taking 2 readings at about 5 min intervals. In the studies of the enzyme kinetics a competitive inhibitor of the reaction was found in plasma. The amount of the inhibitory substances seemed to be nearly constant in the plasma samples studied from normal pregnant women as well as in plasma samples with high enzyme activity (twin-pregnancy) and low enzyme activity (severe pre-eclampsia). The normal enzyme activity pattern showed an increase from about 210 days of pregnancy and towards the term. A coefficient of correlation of plus 0.83 with the more time consuming method using 1-cystine-di-beta-naphtylamide as substrate was found. It was concluded that the present method could replace the method described by Babuna & Yenen (1966) at least from about 210 days of pregnancy and where a rapid answer is necessary.

Adult↗
PubMed1989

[A cystine-containing short-chain peptide as a potential cystine source for parenteral nutrition].

For the first time, in vivo utilization of two highly soluble and stable cystine containing synthetic short chain peptides, N,N'-bis-L-alanyl-L,L-cystine and N,N'-bis-glycyl-L,L-cystine, was investigated in adult rats. Within 5 min after an intravenous bolus, blood samples were drawn (inferior vena cava) and plasma amino acid and peptide levels were determined using RP-HPLC (precolumn derivatization with 1-dimethylaminonaphthalene-5-sulfonylchloride). Both peptides were rapidly cleared from plasma (estimated elimination time: 4 min for the glycyl peptide and less than 2 min for the alanyl peptide). The initial high amounts of N-L-alanyl-L,L-cystine and N-glycyl-L,L-cystine as well as the prompt increase of the constituent free amino acids alanine, glycine and cystine strongly suggest that the peptide disappearance is mainly due to a very fast two-step hydrolysis in the extracellular compartment, presumably catalyzed by soluble and/or plasma membrane bound peptidases. The observed rapid hydrolysis may serve as first evidence that short chain peptides with C-terminal cystine residue may represent efficient sources of free cystine in parenteral nutrition.

Alanine↗
PubMed1990

Depletion of cystine in cystinotic fibroblasts by homocysteine. Synergism of cysteamine with various reducing agents in depletion of cystine from cystinotic fibroblasts.

The present study shows that homocysteine depleted cystine from cystinotic fibroblasts in vitro. No toxic effects were noted as judged by morphology and growth patterns. Efflux of radioactivity from cystinotic cells prelabeled with [35S]cystine was greater in homocysteine-treated cystinotic cells than in untreated controls. This radioactivity was found, by high voltage electrophoresis separation of effluxed products, to consist mainly of [35S]cystine, along with smaller amounts of [35S]homocysteine-cysteine mixed disulfide. When homocysteine and cysteamine were presented together to cystinotic cells at dose levels individually ineffective in removing cystine from these cells, a marked synergistic effect was observed and cystine content fell to 10% of that seen in untreated cystinotic fibroblasts. Similarly, synergistic effects of cystine depletion from cystinotic cells were demonstrated when cells were treated with a combination of cysteamine and dithiothreitol or glutathione. Incubation of cystinotic cells with homocysteine, dithiothreitol, or cysteamine in combination with vitamin C did not yield synergistic effects. The above findings suggest a novel way to probe metabolic processes in these mutant cells. Exploration of these synergistic effects may lead to more efficacious therapeutic protocols for cystinosis.

Ascorbic Acid↗
PubMed1990

Effect of cystine loading and cystine dimethylester on renal brushborder membrane transport.

The effect of loading renal tubule cells with cystine was studied by incubating them with cystine dimethylester. Proline uptake into brushborder membrane vesicles isolated from the cystine loaded cells was not different from that observed into brushborder vesicles isolated from tubules incubated in buffer alone. Incubating brushborder membranes with 2 mM cystine dimethylester for 10 minutes reduced the uptake of proline by 27% after 15 seconds of incubation and by 21% after 60 seconds of incubation. There was no effect after 20 minutes of incubation. Pre-incubating brushborder membrane vesicles with cystine dimethylester had no statistically significant effect on the affinity of proline for the carrier, but did reduce the maximal rate of proline uptake by 49%.

Animals↗
PubMed1987

A cystine-dependent inactivator of tyrosine aminotransferase co-purifies with gamma-cystathionase (cystine desulfurase).

Tyrosine aminotransferase is stable in homogenates of rat liver, but not when L-cystine or L-cysteine is added, which causes the enzyme to be reversibly inactivated due to oxidation of thiol groups. By monitoring inactivation of the aminotransferase in the presence of L-cystine, a factor responsible for this loss of activity was purified from rat liver. The factor required vitamin B6 and co-purified with gamma-cystathionase during numerous steps. Highly purified inactivating factor contained a protein that was identical in size and isoelectric point to cystathionase but also contained a dissimilar peptide that appeared to be unrelated to cystathionase. Cystathionase and the cystine-dependent inactivator shared several catalytic activities, including the hydrolysis of cystathionine, desulfuration of cystine, and desulfhydration of cysteine. During incubation of L-cysteine with the purified factor, hydrogen sulfide was generated but no inactivation of the aminotransferase occurred, suggesting that cysteine-dependent inactivation requires additional mechanisms. An insoluble inactivator of tyrosine aminotransferase that is produced during the reaction may be elemental sulfur, since colloidal suspensions of sulfur also inhibited the enzyme. Another inhibitor fractionated with high molecular weight substances; this may be protein-bound sulfane.

Animals↗
PubMedDate not supplied

Colpocytograms and maternal serum placental cystine aminopeptidase, tissue cystine aminopeptidase, alkaline phosphatase and heat stable alkaline phosphatase activity in monitoring the last four weeks before delivery in high-risk pregnancy.

On the basis of the results of serial enzyme and cytohormonal assays in the last lunar month of gestation in 232 pergnant patients with high-risk pregnancy, it has been shown that the "at term" and inflammatory smears, which persist for over five days before labor, and post-partum" smears, significantly correlate with abnormal (low or decreasing) results of serum placental cystine aminopeptidase activity and with the pathologic course of pregnancy and labor as well as with the poor neonates' condition. The average serum placental and tissue cystine aminopeptidase determinations were the lowest in women with "post-partum" smears or persisting "at term" smears. These activities reached their highest they temporarily decreased. The oxytocinase activity curves in women with cytolytic smears were similar to those in patients with the "before term" smear patterns, which persisted before delivery. The average oxytocinase activity in women with the inflammatory smears was at first the highest and later it decreased most rapidly of all the groups under consideration. The maternal serum alkaline phosphatase and its heat-stable fraction in pregnant patients with "post-partum" and persisting "at term" smears were at first the lowest and just before labor the highest of all the cytologic pregnancy patterns. Colpocytograms confirmed their high prognostic value when compared with the enzyme tests of placental function.

Alkaline Phosphatase↗
PubMed1974

Controlled trial of combinations of hydroxocobalamin-cystine and riboflavine-cystine, in Nigerian ataxic neuropathy.

Chronic cyanide intoxication of dietary origin and riboflavine deficiency are believed to be major aetiological factors in Nigerian tropical ataxic neuropathy. The results are presented of a double-blind controlled therapeutic trial of combinations of large doses of hydroxocobalamin and cystine as cyanide binding agents together with riboflavine or placebos in Nigerian patients suffering from the tropical ataxic neuropathy. No clinical benefit was demonstrable with any of the treatments.

Ataxia↗